Zoetis Inc Q4 2020 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: David Michael Westenberg - Guggenheim Securities, LLC, Research Division - Analyst : Congrats on a great year. Can you give us a little bit of flavor on where Trio is taking share from? I think you mentioned there's some new to the category, but I'm just kind of getting the trend and the flavor, is that legacy, just legacy flee and tick? I mean, what component is heartworm? And basically, what I'm trying to do is get a good sense of how big this can grow in terms of both the heartworm market and the flee and tick market? And then just a second related question on Trio. Is there any synergies, particularly on the sales synergy from the direct-to-consumer marketing campaigns that might be able to benefit maybe derm or maybe even there's a cost synergy?

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : Going back to the diagnostics field. Glenn, you mentioned the growth rate there, I think, 20-plus percent. Can you talk about to what degree that rate is influenced by M&A, if at all? And maybe more broadly about your strategy there, clearly, there's an element of sort of building and catching up, but I'm also curious on sort of how you're trying to differentiate or leapfrog competition broadly from a diagnostics standpoint? And then, Glenn, are you seeing any signs of upward pressure on key input costs as the world thinks about commodity price inflation or at least the potential for it?